<DOC>
	<DOCNO>NCT00701428</DOCNO>
	<brief_summary>Obstructive sleep apnea ( OSA ) highly prevalent condition hypertensive patient . The renin-angiotension-aldosterone-system ( RAAS ) central role blood pressure control . An angiotensin-II-antagonist , Losartan , effective antihypertensive drug . However , patient respond drug bad others , clinical praxis either increase dosage and/or add another drug . There limited data regard impact antihypertensive drug OSA patient , i.e. , whether OSA may constitute subgroup therapy-resistent hypertensive patient . In literature , data , either , whether CPAP treatment may additive blood pressure lower impact certain subgroup .</brief_summary>
	<brief_title>Losartan Hypertensive Men Women With Sleep Apnea Before Continuous Positive Airway Pressure ( CPAP ) Treatment</brief_title>
	<detailed_description>OSA highly prevalent condition hypertensive patient prevalence even high patient drug-resistant hypertension . The renin-angiotension-aldosterone-system ( RAAS ) central role blood pressure control . An angiotensin-II-antagonist , Losartan , effective antihypertensive drug . However , patient respond drug bad others , clinical praxis either increase dosage and/or add another drug . There limited data regard impact antihypertensive drug OSA patient , i.e. , whether OSA may constitute subgroup therapy-resistent hypertensive patient . In literature , data , either , whether CPAP treatment may additive blood pressure lower impact certain subgroup . The investigator include 90 otherwise healthy , untreated hypertensive men woman ( age 50-69 yr , Body-Mass-Index &lt; 35 kg/m2 ; 60 patient OSA , 30 non-OSA ) described . Before start treatment , fast blood sample draw regard neuroendocrine hormone ( adrenaline , noradrenaline , plasma renin activity , angiotensin II , aldosterone , pro-BNP ) cardiovascular biomarkers ( CRP , interleukines , cytokine ) . All subject start Losartan 50 mg 24 h- blood-pressure response blood sample analysis compare OSA non-OSA subject 6 week treatment . In second 6-week period , subject continue Losartan half OSA group ( n=30 ) randomize CPAP 30 patient continue Losartan .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Body Mass Index &lt; 35 kg/m2 Systolic Blood Pressure &gt; =140 mmHg and/or Diastolic Blood Pressure &gt; =95 mmHg No known clinical disease except hypertension No cardiovascular medication ApneaHypopnea Index &lt; 5/h ( OSA ) , Apnea Hypopnea Index &gt; =15/h ( OSA ) Manifest diabetes , liver kidney disease Signs atrial fibrillation former myocardial infarction electrocardiogram</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Sleep Apnea</keyword>
	<keyword>Angiotensin II antagonist</keyword>
	<keyword>CPAP</keyword>
</DOC>